跳至主要内容
临床试验/NCT04092790
NCT04092790招募中不适用

The Identification and Prevention of Sarcopenia in Older Patients in the Acute Hospital Setting

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年4月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
1
主要终点
Muscle mass

研究概览

简要总结

This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.

详细描述

Modern advances in prevention, medical care, and treatments have resulted in an ever-increasing life expectancy and aging of the population. As a result, it is imperative that health care professionals and policy makers develop strategies and new technologies that enable older people to enjoy their advancing years in good health.

Sarcopenia, an age-related decrease in muscle mass, is a major factor in functional decline and frailty and leads to poor quality of life and increased health care costs in older age groups. Because sarcopenia is known to be exacerbated at the time of acute hospital admission, the development of new technologies for the prevention and diagnosis of sarcopenia will have important ramifications in promoting healthy aging in both the acute care and ambulatory settings.

A pilot interventional self-controlled study will be performed in an internal medicine department (internal medicine ward Het) at the Rambam Health Care Campus in Haifa.

Subjects will be evaluated for the risk of sarcopenia by acceptable screening instruments as well as B-mode portable ultrasound. They will then be treated using a stocking-like Virtual Gait Device (VGD) which will be applied to one randomly-assigned lower limb. The VGD is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility.

Confidentiality will be achieved by applying a unique identifier to each trial subject in accordance with Good Clinical Practice standards.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
75 Years 至 —(Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male and female patients 75 years of age and older.
  • •Patients admitted with an acute infection (clinically from a respiratory or urinary source).
  • •Expected length of hospitalization of at least 4 days.
  • •Patients who are conscious and cognitively able to provide written informed consent as determined by a score of 0 on the 4AT scale

排除标准

  • •Male and female patients under 75 years of age.
  • •Expected length of hospitalization of less than 4 days.
  • •A condition limiting the use of the virtual gate device (VGD) due to factors relating to discomfort or safety, including but not limited to: fracture, amputation, local infection, pain, paralysis of one or both lower limbs, cardiac arrhythmia or cardiac pacemaker.
  • •Patients who are unable to or do not provide informed consent for participation.
  • •A score 1 or more on the 4AT scale.

研究组 & 干预措施

Virtual Gate Device (VGD)

Experimental

The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.

干预措施: Virtual Gate Device (VGD) (Device)

结局指标

主要结局

Muscle mass

时间窗: Day 4 of admission or last measurement prior to discharge for a maximum of 10 days.

Determined by B-mode ultrasound measurement.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tzvi Dwolatzky

Director Geriatrics

Rambam Health Care Campus

研究点 (1)

Loading locations...

相似试验

Sarcopenia in Older Patients in the Acute Hospital... | 临床试验